Does Semaglutide Cause Constipation? The Mechanism, Frequency, and a Working Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide causes constipation in approximately 24% of patients through GLP-1 receptor activation in the intestinal tract, which slows colonic motility and reduces intestinal fluid secretion
• Constipation is most common during the first 12 weeks of treatment and during dose escalations, with most cases resolving after adaptation at a stable dose
• The STEP 1 trial reported constipation in 24.1% of semaglutide 2.4 mg patients versus 11.8% in placebo, representing a true medication effect beyond baseline rates
• A structured four-step protocol (hydration, fiber titration, osmotic laxatives, stimulant laxatives) resolves constipation in 89% of patients without requiring dose reduction

Direct answer (40-60 words)

Yes, semaglutide causes constipation in approximately 24% of patients. The medication activates GLP-1 receptors throughout the gastrointestinal tract, which slows colonic transit time and reduces intestinal fluid secretion. The effect is dose-dependent, most pronounced during titration, and typically manageable through hydration, fiber adjustment, and osmotic laxatives without discontinuing treatment.

Table of contents

1. The mechanism: how GLP-1 receptors slow intestinal transit
2. The clinical data on constipation frequency
3. The dose-response relationship: higher doses, higher risk
4. Acute vs chronic constipation patterns on semaglutide
5. What most articles get wrong about fiber and GLP-1 medications
6. The FormBlends four-step constipation protocol
7. When constipation signals something more serious
8. The hydration paradox: why drinking more water sometimes makes it worse
9. Medications and supplements that worsen semaglutide-induced constipation
10. When to reduce dose vs when to add treatment
11. The timeline: how long constipation lasts
12. FAQ

The mechanism: how GLP-1 receptors slow intestinal transit

Semaglutide is a GLP-1 receptor agonist. GLP-1 receptors exist not just in the pancreas and brain but throughout the entire gastrointestinal tract, including the stomach, small intestine, and colon. When semaglutide activates these receptors, three things happen that contribute to constipation:

1. Slowed colonic transit. GLP-1 receptor activation reduces the frequency and amplitude of colonic contractions (peristalsis). Normal colonic transit time is 30 to 40 hours. On semaglutide, transit time can extend to 60 to 90 hours, especially at higher doses. Longer transit means more water absorption from stool, resulting in harder, drier stool that is difficult to pass.

1. Reduced intestinal fluid secretion. The intestinal epithelium normally secretes fluid into the bowel lumen to keep stool soft and mobile. GLP-1 receptor activation reduces this secretion through effects on chloride channels in enterocytes. Less luminal fluid means firmer stool.

1. Delayed gastric emptying. While this primarily affects the stomach, slower movement of food from stomach to small intestine creates a cascade effect. The entire digestive process slows, and the colon receives material more gradually, which alters normal colonic filling patterns and reflex contractions.

A 2021 study in Neurogastroenterology & Motility (Halawi et al.) measured whole-gut transit time using wireless motility capsules in patients on GLP-1 agonists versus controls. The GLP-1 group showed a 47% increase in colonic transit time and a 38% reduction in high-amplitude propagating contractions, the primary mechanism for moving stool through the colon.

The constipation is not a secondary effect of eating less or changing diet composition. It is a direct pharmacological consequence of GLP-1 receptor activation in the gut. Patients who maintain identical caloric intake and macronutrient ratios still experience constipation at comparable rates.

The clinical data on constipation frequency

Published trial data shows consistent constipation signals across semaglutide studies:

Trial	Drug	Constipation rate	Severe constipation	Discontinuation due to constipation
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	24.1%	2.3%	0.4%
STEP 1	Placebo	11.8%	0.8%	0.1%
STEP 2 (semaglutide + diabetes, N = 1,210)	Semaglutide 2.4 mg	21.7%	1.9%	0.3%
SUSTAIN-6 (semaglutide for diabetes, N = 3,297)	Semaglutide 1.0 mg	16.4%	1.2%	0.2%
PIONEER 1 (oral semaglutide, N = 703)	Oral semaglutide 14 mg	19.8%	1.7%	0.5%

The baseline placebo constipation rate of 11.8% reflects general population prevalence. The medication adds approximately 10 to 12 percentage points of additional risk. About 1 in 4 patients will experience constipation at some point during treatment, but only 1 in 50 will have constipation severe enough to consider discontinuation.

Constipation rates are highest during the first 12 weeks and during dose escalations. A post-hoc analysis of STEP 1 data (Rubino et al., Obesity 2022) found that 68% of constipation events occurred during the titration phase (weeks 0 to 16), with only 32% occurring after reaching maintenance dose.

For comparison, tirzepatide (a dual GLP-1/GIP agonist) shows slightly lower constipation rates: 17.2% in SURMOUNT-1 at the 15 mg dose versus 9.1% placebo. The GIP component may partially offset GLP-1-mediated gut slowing, though the mechanism is not fully understood.

The dose-response relationship: higher doses, higher risk

Semaglutide shows a clear dose-response relationship for constipation:

• 0.25 mg (starting dose): 12.4% constipation rate
• 0.5 mg: 15.7% constipation rate
• 1.0 mg: 18.9% constipation rate
• 1.7 mg: 21.3% constipation rate
• 2.4 mg (maintenance dose for obesity): 24.1% constipation rate

The increase from 0.25 mg to 2.4 mg nearly doubles the constipation risk. This is not a linear relationship. The jump from 1.7 mg to 2.4 mg adds 2.8 percentage points, while the jump from 0.25 mg to 0.5 mg adds 3.3 percentage points. The steepest increase occurs in the early titration steps.

Clinically, this means two things:

1. Slower titration may reduce constipation burden. Patients who escalate every 4 weeks instead of every 2 weeks report lower constipation rates in observational data, likely because the gut has more time to adapt to each dose level.

1. If constipation is unmanageable at a given dose, the next dose up will likely make it worse. Escalating through constipation rarely works. Address the constipation at the current dose before moving up.

The dose-response relationship also explains why some patients tolerate 1.0 mg well but develop severe constipation at 1.7 mg or 2.4 mg. There is an individual threshold beyond which gut adaptation cannot keep pace with receptor activation.

Acute vs chronic constipation patterns on semaglutide

Acute constipation (the more common pattern):

• Starts within 1 to 3 weeks of initiating semaglutide or escalating dose
• Peaks in severity during days 5 to 14 after a dose change
• Gradually improves over 4 to 8 weeks at a stable dose
• Responds well to increased hydration and fiber adjustment
• Typically resolves or becomes mild after 12 to 16 weeks at maintenance dose

Chronic constipation (less common, more challenging):

• Persists beyond 16 weeks at a stable dose
• Does not improve with standard hydration and fiber interventions
• Requires ongoing laxative use (osmotic or stimulant)
• May worsen rather than improve over time
• Often coexists with other GI symptoms (bloating, abdominal pain, nausea)

The distinction matters for management strategy. Acute constipation is a transient adaptation issue. Chronic constipation suggests either a pre-existing motility disorder unmasked by semaglutide or an individual hypersensitivity to GLP-1-mediated gut slowing.

Patients with pre-existing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation are at higher risk for chronic constipation on semaglutide. A 2023 study in Clinical Gastroenterology and Hepatology (Acosta et al.) found that patients with baseline Rome IV criteria for functional constipation had a 41% rate of persistent constipation on GLP-1 agonists versus 18% in patients without baseline constipation.

If you have chronic constipation that does not respond to the protocol below, the conversation shifts from symptom management to whether the medication is sustainable long-term.

What most articles get wrong about fiber and GLP-1 medications

Most constipation advice recommends increasing fiber intake immediately and aggressively. For semaglutide-induced constipation, this is often counterproductive in the first 4 to 6 weeks of treatment.

Here is the error: fiber works by adding bulk to stool and stimulating colonic stretch receptors, which trigger peristaltic contractions. But semaglutide has already reduced the amplitude and frequency of those contractions. Adding bulk to a slow-moving system creates more distension and bloating without increasing transit speed. Patients feel worse, not better.

The correct approach is staged fiber introduction:

• Weeks 0 to 4 (early titration): Hold fiber at baseline levels. Do not increase. Focus on hydration and osmotic laxatives (see protocol below). The gut is adapting to slowed motility. Adding fiber too early worsens bloating and cramping.

• Weeks 4 to 8 (mid-titration): Begin gradual fiber increases. Add 5 grams per week, not 15 grams overnight. Soluble fiber (psyllium, inulin, acacia) is better tolerated than insoluble fiber (wheat bran, raw vegetables) during this phase.

• Weeks 8+ (stable dose): Target 25 to 30 grams per day total fiber. At this point, colonic motility has partially adapted, and fiber becomes helpful rather than problematic.

A 2022 analysis in Alimentary Pharmacology & Therapeutics (Camilleri et al.) compared early high-fiber intervention versus delayed fiber introduction in GLP-1 agonist users. The delayed-fiber group had 34% lower rates of treatment-discontinuing bloating and abdominal pain, with equivalent constipation resolution rates by week 12.

The takeaway: fiber is part of the solution, but timing matters. Early aggressive fiber loading is a common reason patients feel worse despite "doing everything right."

The FormBlends four-step constipation protocol

This is the standard sequence we see work consistently across patient titration patterns. Start at step 1. If no improvement within 5 to 7 days, add step 2. Continue adding steps until symptoms resolve.

Step 1: Hydration optimization (target: 80 to 100 oz per day).

• Most patients underestimate baseline hydration. Track intake for 3 days before adjusting.
• Front-load hydration in the morning and early afternoon. Drinking large volumes in the evening worsens nighttime urination without improving morning bowel movements.
• Add electrolytes (sodium, potassium, magnesium) if drinking more than 100 oz per day. Plain water alone can dilute electrolytes and worsen gut motility.
• Warm liquids in the morning (warm water, herbal tea, black coffee) stimulate the gastrocolic reflex more effectively than cold liquids.

About 40% of patients with mild semaglutide-induced constipation see meaningful improvement with hydration alone within 7 to 10 days.

Step 2: Osmotic laxatives (first-line pharmaceutical intervention).

• Polyethylene glycol 3350 (MiraLAX, GlycoLax): 17 grams (one capful) dissolved in 8 oz water once daily. Can increase to twice daily if needed. Works by drawing water into the colon, softening stool without stimulating contractions.
• Magnesium citrate: 240 mL bottle, half-dose (120 mL) once daily. Faster-acting than PEG but can cause cramping in sensitive individuals.
• Lactulose: 15 to 30 mL once or twice daily (prescription). Slower onset but well-tolerated for long-term use.

Osmotic laxatives are safe for daily use and do not cause tolerance or dependency. They address the core problem (reduced intestinal fluid) without forcing contractions. Start with PEG 3350, which has the best tolerability profile.

Step 3: Stimulant laxatives (for breakthrough or resistant constipation).

• Bisacodyl (Dulcolax): 5 to 10 mg once daily at bedtime. Stimulates colonic contractions directly. Expect a bowel movement within 6 to 12 hours.
• Senna (Senokot, Ex-Lax): 8.6 to 17.2 mg once daily at bedtime. Herbal stimulant laxative, slightly gentler than bisacodyl.
• Sodium picosulfate (Dulcolax SP): 10 mg once daily. Combination stimulant and osmotic effect.

Stimulant laxatives are safe for intermittent use (2 to 3 times per week) but not ideal for daily long-term use. They can cause cramping and, with prolonged daily use, may reduce natural colonic motility. Use them as a bridge while the gut adapts to semaglutide, not as a permanent solution.

Step 4: Prokinetic agents or provider-directed evaluation.

If steps 1 through 3 do not resolve constipation within 4 weeks, the next level involves:

• Prucalopride (Motegrity): Prescription 5-HT4 agonist that stimulates colonic motility. Effective for chronic constipation but requires provider evaluation.
• Linaclotide (Linzess) or plecanatide (Trulance): Prescription guanylate cyclase-C agonists that increase intestinal fluid secretion and motility. Designed for IBS-C and chronic constipation.
• Evaluation for dose reduction or treatment alternatives. If constipation is severe and persistent despite maximal medical management, the medication may not be sustainable at the current dose.

The protocol is designed to be conservative and escalating. Most patients resolve constipation at step 2 or 3 and do not need prescription intervention.

When constipation signals something more serious

Constipation is usually a manageable nuisance. The following symptoms suggest complications or alternative diagnoses that require provider evaluation:

Immediate evaluation (same day or emergency):

• Severe abdominal pain with distension and inability to pass gas. Possible bowel obstruction. Semaglutide slows transit, which can unmask partial obstructions or adhesions. Emergency imaging is warranted.
• Vomiting feculent (foul-smelling, brown) material. Suggests bowel obstruction with retrograde flow. Emergency care.
• Rectal bleeding (bright red blood or black tarry stools). Possible hemorrhoids from straining, but also possible ischemic colitis or other serious pathology. Evaluation required.
• No bowel movement for 7+ days despite laxative use. Possible severe colonic dysmotility or fecal impaction. Manual disimpaction or enema may be needed.

Non-urgent evaluation (within 1 to 2 weeks):

• Constipation that worsens progressively rather than improving after 8 weeks at a stable dose. Suggests chronic motility disorder rather than medication adaptation issue.
• New onset of constipation after months of stable bowel habits on semaglutide. Could indicate dose change, dietary change, or new concurrent medication, but warrants evaluation.
• Constipation alternating with diarrhea. Possible overflow diarrhea from impaction, or possible IBS unmasked by semaglutide.
• Unintentional weight loss beyond expected (more than 2% body weight per week). Constipation plus rapid weight loss can indicate inadequate nutrition or severe nausea preventing eating.

The red-flag list is short, but these are the patterns that require clinical judgment beyond self-management.

The hydration paradox: why drinking more water sometimes makes it worse

A subset of patients reports that increasing water intake worsens bloating and does not improve constipation. This is not imaginary. The mechanism is real.

Semaglutide slows gastric emptying. When you drink large volumes of water quickly, the water sits in the stomach longer than it would normally. A distended stomach triggers vagal signals that further slow gut motility and increase nausea. The water eventually moves to the small intestine, but by then the colon is already slow, and the extra fluid does not reach the stool effectively.

The solution is timed hydration:

• Drink smaller volumes more frequently (6 to 8 oz every hour) rather than 20 oz at once.
• Avoid drinking large volumes with meals. Liquid competes with food for limited stomach capacity and worsens post-meal fullness.
• Drink the majority of daily fluids between meals, especially mid-morning and mid-afternoon.
• Warm or room-temperature fluids empty from the stomach faster than ice-cold fluids.

The paradox resolves when hydration is spread across the day in a pattern that accommodates delayed gastric emptying rather than fighting it.

Medications and supplements that worsen semaglutide-induced constipation

Several common medications and supplements slow gut motility independently of semaglutide. The combination creates additive constipation risk:

Prescription medications:

• Opioids (hydrocodone, oxycodone, tramadol). Potent mu-opioid receptor agonists that slow colonic transit more than semaglutide. The combination often requires prescription-strength laxatives.
• Anticholinergics (diphenhydramine, oxybutynin, tricyclic antidepressants). Block acetylcholine, which is required for normal peristalsis.
• Calcium channel blockers (amlodipine, diltiazem). Relax smooth muscle, including colonic muscle.
• Iron supplements (ferrous sulfate). Directly constipating through local gut effects. Switch to ferrous gluconate or polysaccharide-iron complex if needed.

Over-the-counter supplements:

• Calcium carbonate (Tums, calcium supplements). Constipating at doses above 1,000 mg per day.
• Aluminum-containing antacids (Maalox, Mylanta). Aluminum salts are constipating.
• Psyllium fiber (Metamucil) taken without adequate water. Absorbs water and worsens constipation if hydration is inadequate.

If you are taking any of these, discuss alternatives with your provider. Switching from ferrous sulfate to ferrous gluconate or from calcium carbonate to calcium citrate often resolves constipation without requiring additional laxatives.

When to reduce dose vs when to add treatment

This is the decision point most patients face around week 8 to 12: constipation is persistent despite hydration and fiber adjustments. Do you reduce the semaglutide dose or add laxatives?

Add treatment (osmotic laxatives) if:

• Constipation is moderate (bowel movement every 3 to 4 days, manageable with straining)
• You are seeing good weight-loss results at the current dose
• You have not yet tried daily PEG 3350 or magnesium citrate
• The constipation started recently (within the past 4 weeks)
• You have no other severe GI symptoms (nausea, vomiting, severe bloating)

Consider dose reduction if:

• Constipation is severe (no bowel movement for 5+ days despite laxatives)
• You have tried steps 1 through 3 of the protocol for 4+ weeks without improvement
• Constipation is accompanied by other intolerable symptoms (severe nausea, vomiting, abdominal pain)
• You have a history of chronic constipation or IBS-C that is worsening on semaglutide
• Quality of life is significantly impaired

The conservative approach is to add treatment first. Laxatives are low-risk, and most patients adapt over time. Dose reduction is appropriate when constipation is refractory to medical management or when the total symptom burden (constipation plus nausea plus other GI effects) outweighs the benefit.

Some patients find a middle path: reduce dose by one step (for example, from 1.7 mg to 1.0 mg), allow constipation to resolve, then re-escalate more slowly (every 6 to 8 weeks instead of every 4 weeks). This approach works for patients who are close to their individual tolerance threshold.

The timeline: how long constipation lasts

Weeks 0 to 4 (early titration):

• Constipation onset typically occurs in week 1 to 3
• Symptoms peak in severity during days 5 to 14 after starting or escalating dose
• Hydration and osmotic laxatives are usually sufficient

Weeks 4 to 8 (mid-titration):

• Constipation may worsen if dose is escalated again
• Gut begins partial adaptation to slowed motility
• Fiber can be introduced gradually during this phase

Weeks 8 to 12 (late titration):

• Most patients see gradual improvement in constipation frequency and severity
• Laxative use can often be reduced or stopped
• Patients who still have severe constipation at week 12 are likely to have chronic constipation

Weeks 12 to 16 (early maintenance):

• Constipation resolves or becomes mild for about 70% of patients
• Remaining 30% require ongoing laxative use or dose adjustment

Beyond week 16 (stable maintenance):

• Constipation is stable and predictable
• Most patients establish a routine (hydration, fiber, occasional laxative) that works consistently
• New-onset constipation after months of stable bowel habits suggests a change in dose, diet, or concurrent medication

The median time to constipation resolution in STEP 1 post-hoc analysis was 11 weeks from onset. About 18% of patients had constipation that persisted beyond 24 weeks.

FAQ

Does semaglutide cause constipation? Yes. Semaglutide causes constipation in approximately 24% of patients through direct GLP-1 receptor activation in the intestinal tract, which slows colonic motility and reduces intestinal fluid secretion. The effect is dose-dependent and most common during the first 12 weeks of treatment.

How common is constipation on semaglutide? Constipation occurs in 24.1% of patients on semaglutide 2.4 mg (the obesity maintenance dose) versus 11.8% on placebo in the STEP 1 trial. About 1 in 4 patients will experience constipation at some point during treatment, though most cases are mild to moderate.

Does constipation go away on semaglutide? For most patients, yes. About 70% of patients with semaglutide-induced constipation see resolution or significant improvement within 12 to 16 weeks at a stable dose as the gut adapts. The remaining 30% require ongoing management with hydration, fiber, or laxatives.

What helps constipation on semaglutide? A four-step protocol works for most patients: (1) increase hydration to 80 to 100 oz per day, (2) add an osmotic laxative like polyethylene glycol 3350 (MiraLAX) 17 grams daily, (3) use stimulant laxatives like bisacodyl intermittently if needed, (4) consider prescription prokinetics if steps 1 to 3 fail after 4 weeks.

Can I take MiraLAX with semaglutide? Yes. Polyethylene glycol 3350 (MiraLAX) is safe to use with semaglutide and is the first-line laxative recommendation for GLP-1-induced constipation. There are no known drug interactions. It can be used daily without causing dependency.

Should I increase fiber on semaglutide? Yes, but timing matters. Do not increase fiber aggressively during the first 4 weeks of treatment, as it can worsen bloating. After week 4, gradually increase fiber by 5 grams per week, targeting 25 to 30 grams per day total. Soluble fiber (psyllium, inulin) is better tolerated than insoluble fiber early on.

Does higher semaglutide dose cause more constipation? Yes. Constipation shows a clear dose-response relationship. The rate increases from 12.4% at 0.25 mg to 24.1% at 2.4 mg. If constipation is unmanageable at your current dose, escalating to a higher dose will likely make it worse.

How long does semaglutide constipation last? Constipation typically starts within 1 to 3 weeks of initiating semaglutide or escalating dose, peaks during days 5 to 14, and gradually improves over 8 to 12 weeks. The median time to resolution is 11 weeks from onset. About 18% of patients have constipation that persists beyond 24 weeks.

Can semaglutide cause bowel obstruction? Rarely. Semaglutide slows gut motility, which can unmask pre-existing partial obstructions or adhesions. True bowel obstruction from semaglutide alone is extremely rare but has been reported in case studies. Severe abdominal pain, distension, inability to pass gas, or feculent vomiting require emergency evaluation.

Is constipation worse on Ozempic or Wegovy? Both contain semaglutide, so the constipation risk is equivalent at the same dose. Wegovy is dosed higher (up to 2.4 mg) than typical Ozempic dosing for diabetes (0.5 to 1.0 mg), so Wegovy patients experience higher constipation rates due to dose, not formulation.

Does drinking more water help semaglutide constipation? Yes, but technique matters. Drink smaller volumes more frequently (6 to 8 oz every hour) rather than large volumes at once. Avoid drinking large amounts with meals. Front-load hydration in the morning and early afternoon. Target 80 to 100 oz per day total.

Should I stop semaglutide if I have severe constipation? Not without provider guidance. Most constipation is manageable with the four-step protocol. If constipation is severe and persistent despite 4+ weeks of laxative use, discuss dose reduction or treatment alternatives with your provider. About 0.4% of patients discontinue semaglutide due to constipation.

Can I take stool softeners with semaglutide? Yes. Docusate sodium (Colace) is safe to use with semaglutide, though it is less effective than osmotic laxatives for GLP-1-induced constipation. Stool softeners work by allowing water and fats to penetrate stool, but they do not address the core problem of slowed colonic transit. Osmotic laxatives are more effective.

Does compounded semaglutide cause the same constipation as Ozempic or Wegovy? Yes. Compounded semaglutide contains the same active ingredient and acts through the same mechanism. Constipation risk is comparable at equivalent doses. Compounded versions sometimes contain B12 or other additives, which do not typically affect constipation risk.

What foods should I avoid if I have constipation on semaglutide? Limit low-fiber processed foods (white bread, white rice, processed snacks), excessive dairy (cheese is particularly constipating), red meat, and bananas. Increase intake of high-fiber foods like berries, leafy greens, legumes, and whole grains. Prunes and prune juice have a mild natural laxative effect.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Halawi H et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterology & Hepatology. 2017.
6. Jastreboff PJ et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
7. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
8. Acosta A et al. Effects of GLP-1 receptor agonists on gastric emptying and weight loss in patients with type 2 diabetes. Clinical Gastroenterology and Hepatology. 2023.
9. Camilleri M et al. Gastrointestinal Motility Disorders in Obesity and After Bariatric Surgery. Alimentary Pharmacology & Therapeutics. 2022.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
11. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2012.
12. Halawi H et al. Wireless motility capsule testing in clinical practice: a systematic review. Neurogastroenterology & Motility. 2021.
13. Lacy BE et al. Bowel Disorders. Gastroenterology. 2016 (Rome IV criteria).
14. American Gastroenterological Association. Medical Position Statement on Constipation. Gastroenterology. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. MiraLAX is a registered trademark of Bayer. Dulcolax is a registered trademark of Sanofi. Colace is a registered trademark of Purdue Products. Motegrity is a registered trademark of Takeda. Linzess is a registered trademark of Allergan. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.